Patrick Hall

Dr. Hall’s career started at Genentech where he was on the medical affairs team that launched Rituxan and Herceptin. Dr. Hall was also a member of the Rituxan and Herceptin clinical development teams at Genentech facilitating and monitoring clinical trials. At Genomic Health, Dr. Hall formed and led the medical science liaison team and was involved with the launch of the Breast, Colon and Prostate assays. Dr. Hall was the Executive Director of Medical Affairs at Castle Biosciences and the first Medical employee where he established a medical affairs team to support the company’s cutaneous melanoma test. He has more than 20 years of industry experience.